In a significant breakthrough, scientists have developed a genetically modified virus that targets and eliminates lethal brain cancer tumors. This advancement in medical science allows a single injection of the modified virus to activate the body’s immune system to combat and eradicate cancer cells, particularly in cases of glioblastoma, one of the most aggressive cancer types.
The innovative therapy, pioneered by researchers at Mass General Brigham and Dana-Farber Cancer Institute, involves using an oncolytic virus, a modified version of the herpes simplex virus. Glioblastoma has been challenging to treat due to its ability to evade the body’s natural immune response, making it a “cold” tumor.
According to Kai Wucherpfennig, MD, PhD, from the Dana-Farber Cancer Institute, previous immunotherapies have not been effective in treating glioblastoma because the cancer lacks infiltration by immune cells. However, the new approach shows promise in bringing critical immune cells into the tumor.
After injection, the modified virus selectively reproduces within cancer cells, destroying them without harming healthy brain tissue. A clinical trial involving 41 patients with recurrent cancer demonstrated significant results, with the treatment not only destroying cancer cells but also recruiting T-cells deep into the brain to continue the fight against the disease.
Data published in the journal Cell revealed that patients, especially those with existing antibodies against the virus, survived longer than expected. E. Antonio Chiocca, MD, PhD, from Mass General Brigham, believes this breakthrough could revolutionize cancer treatment, potentially ending a 20-year stalemate in glioblastoma therapy.
The study found that patients who had T-cells closer to the dying cancer lived longer, indicating a positive impact of the body’s immune system in combating brain tumors. This discovery suggests a promising shift in the standard of care for glioblastoma, offering new hope for patients battling this challenging cancer.